BioNTech SE (BNTX) Operating Income (2018 - 2025)

BioNTech SE has disclosed Operating Income across 8 years of filings, most recently posting -$375.8 million for Q4 2025.

• Operating Income for Q4 2025 came in at -$375.8 million, down 336.63% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 9.74% YoY), and the FY2025 annual result was -$1.6 billion, down 13.02% from the prior year.
• Operating Income came in at -$375.8 million for Q4 2025 at BioNTech SE, down from -$54.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $5.6 billion in Q3 2021 to a low of -$1.0 billion in Q2 2024.
• The 5-year median for Operating Income is $362.5 million (2024), against an average of $1.5 billion.
• Across the five-year window, Operating Income jumped 5574.02% in 2021 and tumbled 575.48% in 2025, its largest moves.
• BioNTech SE's Operating Income stood at $5.4 billion in 2021, then plunged by 37.51% to $3.4 billion in 2022, then tumbled by 83.15% to $566.2 million in 2023, then slumped by 71.95% to $158.8 million in 2024, then tumbled by 336.63% to -$375.8 million in 2025.
• The last three Operating Income figures came in at -$375.8 million (Q4 2025), -$54.8 million (Q3 2025), and -$567.2 million (Q2 2025), per Business Quant data.